Information Provided By: 
Fly News Breaks for January 15, 2019
INSM
Jan 15, 2019 | 08:10 EDT
Canaccord analyst Dewy Steadman raised his price target on Insmed to $32 from $20 following its "blowout" preannouncement last week. The analyst is cautiously optimistic about 2019 performance as even a rock-bottom base revenue assumption is above consensus revenue. He also believes Arikayce will become core to the NTM treatment paradigm over time, making current valuation an attractive entry points for investors. Steadman reiterated his Buy rating on Insmed shares.
News For INSM From the Last 2 Days
There are no results for your query INSM
